A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

ConclusionsThe cytarabine and daunorubicin in CPX-351 liposomes were metabolized and excreted similarly to conventional formulation; however, plasma pharmacokinetics were altered. CPX-351 did not prolong the QT interval, suggesting that CPX-351 may induce less cardiotoxicity than previously reported for conventional daunorubicin.Trial registrationClinicaltrials.gov identifier: NCT02238925.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research